Abstract. Resistance to antimalarial chemotherapy is one of the greatest difficulties for the control of malaria transmission. Seventy patients with Plasmodium falciparum malaria were included in a study of resistance to chloroquine and sulfadoxine-pyrimethamine therapy. Resistance levels RI, RII, and RIII were established. Eighteen infections (51%) cleared after chloroquine treatment and did not recur within 28 days of follow-up; these were classified as sensitive. Ten infections (29%) were resistant at the RI level. Resistance at level RII was observed in 5 (14%) cases, and RIII resistance was demonstrated in 2 infections (6%). With sulfadoxine-pyrimethamine, 28 (80%) infections were classified as sensitive. Six infections (17%) showed resistance at level RII, and 1 (3%) infection was resistant at the RI level. Resistance at level RIII was not observed. In a microtest for chloroquine and sulfadoxinepyrimethamine sensitivity in vitro, schizont development was accomplished successfully in 70 blood samples. In vitro resistance to chloroquine was demonstrated in 15 of 70 (21%) of all isolates. Eight of 70 (11%) of all isolates showed resistance to sulfadoxine-pyrimethamine. Diversity of response of P. falciparum to the studied antimalarial drugs in the Guayana area of Venezuela is considered a problem restricting the control of malaria in this geographical area. A constant evaluation program monitoring P. falciparum drug sensitivity is necessary for preserving the efficacy of the established treatment.
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After a successful eradication program implemented over several decades, malaria is now endemic in Venezuela in patchy forest areas where activities associated with gold mining are limiting control efforts. From 1992 to 1995, Plasmodium falciparum infections and outbreaks were registered only in remote areas in southern Venezuela, in 11 municipalities that are located in Bolívar State and Amazonas and Delta Amacuro territories. Bolívar State has contributed more than 60% of all malaria cases in Venezuela; of these, 20% correspond to P. falciparum infections. On average, the infection rates of the parasite reach 2 cases per 1,000 inhabitants among a population composed mainly of gold and diamond miners and indigenous groups.
Resistance to antimalarial chemotherapy is one of the obstacles for the control of malaria transmission in various regions of the world. The adequate use of antimalarial drugs is essential for reducing the high morbidity and mortality associated with P. falciparum malaria in nonimmune hosts. Therefore, knowledge of the geographical distribution of P. falciparum strains that are resistant and the identification of the severity of this resistance are important in the choice of an effective therapeutic regimen.
Chloroquine resistance was first reported in Venezuela, 1 and soon after was confirmed in several countries. Since 1975, very few studies on resistant P. falciparum strains have been carried out in Venezuela; some of them have shown different resistance levels in vivo for chloroquine 2 (Navarrete L and others, unpublished data) and in vitro for sulfa and pyrimethamine. 3 For instance, a previous study on P. falciparum chloroquine sensitivity in the municipality of Dalla Costa demonstrated that 93.3% of cases were resistant to this drug. 2 The majority (35-40%) of malaria cases in Venezuela occur in the municipality of Domingo Sifontes (Venezuelan Amazonia). In the last 15 years, this situation has been the consequence of unorganized mining and an increase in uncontrolled migrations of people with low malarial immunity into the area, resulting in the epidemiologic conditions for the transmission of malaria. These recent changes in the area's demographics will not be quantified until the next national census in 2000.
In this study, resistance to chloroquine and sulfadoxinepyrimethamine of P. falciparum strains was assessed as a clinical study of drug efficacy in patients from Bolívar State, Venezuela.
MATERIALS AND METHODS
Study region. The study was conducted in a tropical region 34,571 km 2 in area situated at 7Њ15ЈN, 61Њ26Ј W at the municipality of Domingo Sifontes, Venezuela, which is characterized by an intense and almost exclusive exploitation of gold with a very unstable population varying from 10,000 to 20,000 inhabitants living in precarious housing conditions. Because of these circumstances, the contact between humans and vectors is facilitated, which can be considered as one of the epidemic factors or the main factor responsible for the high level of malaria transmission in this region. According to D. Sawyer (unpublished data), the region can be classified as ''rural area open garimpo type 2.'' A tropical rainforest climate prevails, with an average annual precipitation of 1,200 mm, a mean temperature of 18ЊC, a relative humidity of 80%, and an altitude near 300 meters. Transmission of malaria in this area is seasonal, with peaks at the beginning (April-June) and at the end (October-December) of the rainy season. In 1994, the annual parasite index in this municipality was 352 per 1,000 inhabitants (22.7% P. falciparum).
Studied population. Seventy patients with P. falciparum malaria from mining areas in the municipality of Domingo Sifontes were diagnosed at the malaria field station and in the General Hospital in Tumeremo, Bolívar State, Venezuela. A total of 108 patients originally were selected for the study, but 11 patients tested positive for chloroquine in urine and 27 patients began the protocol but did not finish. The final group comprised 70 patients: 62 men and 8 women. Their ages ranged from 14 to 66 years (mean ϭ 30; median ϭ 31.7). Excluded from the study were patients with clinical evidence of severe infection (cerebral, lung, or renal failure), patients treated with chloroquine or quinine up to 15 days before admission to the study, those treated with sulfonamides 30 days before admission, and those with a positive standard urinary excretion test for antimalarial drugs the day of admission. All patients were required to provide informed consent before participation in the study. The study was reviewed and approved by the Ethical Committee of the Tropical Medicine Institute of the University of Central Venezuela.
For the in vivo study of P. falciparum sensitivity to antimalarial drugs, patients were admitted to the General Hospital of Tumeremo for 7 days. Chemotherapy was given at random according to the following regimens. In group A, 35 patients first received 600 mg of chloroquine diphosphate (Pharmamed Laboratories, Valleta, Malta) orally, followed by 300 mg after 6, 24, and 48 hr (total oral dose, 1,500 mg). In group B, 35 patients received 1,575 mg of sulfadoxinepyrimethamine (Fansidar; Medifarm, Brussels, Belgium) orally.
Antimalarial medications were given under medical supervision. During the first 7 days, patients were evaluated daily, verifying fever clearance and disappearance of clinical symptoms. Parasitemias were quantified by counting the number of parasites against 100 leukocytes and assuming a leukocyte count of 5,000/l. Drug absorption was tested by the standard urinary excretion test for antimalarial drugs using Dill-Glazko 4 reagent the second day after beginning chemotherapy. On the seventh day, patients were discharged from the hospital and instructed to come back for weekly follow-up visits on the 14th, 21st, and 28th days after treatment had started. In vivo response to chemotherapy was evaluated according to World Health Organization 5 criteria.
For the in vitro study, blood samples were collected from 70 patients. A microtest for in vitro P. falciparum sensitivity to chloroquine and sulfadoxine-pyrimethamine was conducted following a modification of the technique descried by K. Rieckmann (World Health Organization, unpublished data).
Before doses were administered, microtiter plates (MARK II; WHO Standard Microtest Production Unit, Manila, Philippines) were used. Two tenths of a milliliter of venous blood was collected from each patient in heparinized tubes and mixed with 1.8 ml of RPMI 1640 culture medium. Fifty microliters were added to each well in one column of the predosed plates.
The test plates were placed in a candle jar and incubated at 38ЊC for 28-32 hr. At the end of the incubation period, blood smears were prepared and stained with Giemsa. For each drug concentration tested, the number of schizonts per 200 asexual parasites was determined. Isolates with a schizont maturation of less than 10% in the control wells were not evaluated. In the sulfadoxine-pyrimethamine tests, only schizonts with a normal morphology and at least 8 nuclei were counted.
Drug resistance was assumed if schizont maturation was observed at 8 pmol of chloroquine per well. In the case of sulfadoxine-pyrimethamine, a cut-off point was established in any well registering inhibition of 90% of schizonts with 8 or more nuclei.
For each drug, the respective effective concentrations (ECs) at levels EC 50 , EC 90 , and EC 99 were computed by conducting a logarithmic dose-response test where transformation from trophozoites to schizonts took place in 50, 90, and 99% of the parasites, respectively. 6 Regression lines for the respective antimalarial drugs were plotted using the SAS/ STAT 6.03 program (SAS Inc., Cary, NC).
Patients who relapsed were treated with 500 mg of quinine sulfate at 8-hr intervals for 7 days plus 250 mg of tetracycline at 6-hr intervals for 7 days. This treatment cured the patients.
RESULTS
All patients had acquired malaria in Venezuelan Amazonia (58.6% in Tumeremo, 31.4% in Dalla Costa, and 10% in San Isidro municipalities). Baseline clinical and laboratory characteristics on admission are shown in Table 1 . Initial parasite counts ranged from 3,020 to 72,430/mm 3 (geometric mean density 14,973/mm 3 for chloroquine and 14,713/mm Standard urinary tests for antimalarial compounds using Dill-Glazcko reagent were positive in all patients included in the in vivo study on the second day after chemotherapy had started. Eighteen infections (51%) treated with chloroquine cleared after treatment and did not recur within 28 days of follow-up. These were classified as sensitive. Ten infections (29%) were resistant at level RI. Level RII resistance was observed in 5 (14%) cases. Two infections (6%) demonstrated resistance at level RIII. With sulfadoxine-pyrimethamine, 28 (80%) infections were classified as sensitive. Six (17%) were resistant at level RII and 1 (3%) was resistant at level RI. Resistance at level RIII was not observed (Table 1) .
In a microtest for chloroquine and sulfadoxine-pyrimethamine sensitivity, in vitro schizont development occurred successfully in 70 blood samples. In vitro resistance to chloroquine was demonstrated in 15 of 70 (21%) of all isolates. Eight of 70 (11%) isolates were resistant to sulfadoxinepyrimethamine. The responses to these 2 antimalarial drugs are shown in Tables 2 and 3 . The logarithms for the EC 50 , EC 90 , and EC 99 of the 2 antimalarial drugs are given in Table  4 . These represent the concentrations in which 50, 90, and 99% of the parasites failed to transform, respectively. The regression lines for the same 2 antimalarial compounds are shown in Figures 1 and 2 . DISCUSSION This is the first study carried out in the central western mining areas of Bolívar State, Venezuela, on P. falciparum susceptibility in vivo and in vitro to the antimalarial drugs used in the treatment of this disease. During 1997, malaria incidence in Bolívar State was 10,000 cases, of which 1,634 were caused by P. falciparum from the municipality of Domingo Sifontes. In rural and mining areas of this municipality, the control of malaria is coordinated and supervised by field inspectors. Chloroquine was the drug used most often by the Bolívar State Malaria Control Program before 1983 and by the middle of 1984. During this time, the weekly distribution of chloroquine-primaquine did not even reach 70% of the population (Navarrete L and others, unpublished data). Added to this low percentage of drug administration, in March 1995, therapy against P. falciparum was changed radically without a previous study of chloroquine efficacy. The high pressure overimposed on this drug response was one of the most important factors in the appearance of in- creased resistance of P. falciparum,, as noted by Young and Moore. 7 In mining areas of the municipality, self-medication with diverse antimalarial drugs is frequent; such drugs include medicinal plants, chloroquine, and other patented drugs. As is known, self-medication and subcurative doses favor the selection of resistant parasite populations, which are frequent in areas of high malarial transmission. [8] [9] [10] [11] [12] [13] [14] Another factor that may influence the development of high resistance of P. falciparum to chloroquine (although no studies have been performed) could be the uncontrolled population migration movements within and into and out of the municipality of Domingo Sifontes and surrounding areas, as proposed above. Similar results have been showed by many authors. 13, [15] [16] [17] [18] [19] Our results indicate a direct correlation between the geographical dispersion and the different resistance rates. Similar observations have been pointed out in Brazilian Amazonia. [20] [21] [22] Moderate resistance of P. falciparum was demonstrated in vivo to the sulfadoxine-pyrimethamine combination. Twenty percent of the cases exhibited a variable grade of resistance (RI, 17.1%; RII, 2.9%). The in vitro resistance response was 11%, with a dose range between the EC 50 and EC 99 values (0.02 and 1,027.0 m/liter, respectively).
The diversity of chloroquine and sulfadoxine-pyrimethamine antimalarial responses against P. falciparum in the municipality of Domingo Sifontes is considered a problem that restricts the control of malaria in areas of unorganized mining. This diversity of responses suggests the requirement of constant evaluation programs on drug efficacy and the correct use of antimalarial drugs in order to preserve the potential curative power of established treatments.
In mining regions, early diagnosis and immediate treatment are fundamental for the control of malaria; they should be available everywhere that malaria occurs. Correct treatment of malaria shortens the duration of the disease and considerably reduces complications and deaths. However, in areas where malaria is endemic, development of resistance to the medications used in treatment of noncomplicated malaria is unavoidable. Clearly, the appropriate diagnosis for promptly detecting treatment failures and the opportune selection of alternative medication for such cases are important.
In Venezuela, the National Program of Malaria Therapeutic Outlines governs all the regions where malaria occurs. In Bolívar State, because of the presence of P. falciparum strains that are resistant to chloroquine and sulfadoxine-pyrimethamine, use of mefloquine and quinine could be necessary. In Venezuela, P. falciparum strains resistant to these last 2 medications have not been demonstrated (Caraballo A, unpublished data). Therefore, in this area, it is necessary to know the epidemic factors that determine the distribution of the parasite and the kinds of drugs to which the parasite is resistant. The constant evaluation of the antimalarial medications used is important.
This work has demonstrated a high resistance in vivo of P. falciparum to chloroquine (48.4%), with diverse resistance levels (RI, 28.5%; RII, 14.2%; RIII, 5.7%). Moreover, the in vitro study demonstrated resistance to chloroquine in 21% of isolates, with EC 50 and EC 99 values of 1.71 and 24.57 m/liter, respectively. In view of these findings, continual evaluation of treatment programs is extremely important.
